Table 1.
Clinical, neuroradiological and hormonal characteristics of all patients, collected before starting somatostatin analogues
| Characteristics | Values |
|---|---|
| Included in the previous study (group 1), n (%) | 21 (72) |
| New patients (group 2), n (%) | 8 (28) |
| Age, years | 50 ± 14.9 |
| Female, n (%) | 21 (72) |
| Neuroradiological findings at diagnosis | |
| Macroadenoma, n (%) | 19 (66) |
| Microadenoma, n (%) | 8 (28) |
| Indirect signs of adenoma, n (%) | 1 (3) |
| MRI not performed, n (%) | 1 (3) |
| TNS before starting SAs | |
| Yes | 20 (69) |
| No | 9 (31) |
| Hormonal findings before starting SAs | |
| IGF-1, ng/ml (SDS) | 548 ± 302 (6 ± 4.6) |
| Mean GH, ng/ml | 6.04 ± 5.3 |
| GH nadir, ng/ml | 4.2 ± 4.8 |
Data are expressed as number, percentage (%) and mean ± SDS
MRI magnetic resonance imaging, SAs somatostatin analogues ,TNS transphenoidal surgery